Literature DB >> 30310440

Resistant Hypertension: A Real Entity Requiring Special Treatment?

Stefano Taddei1, Rosa Maria Bruno1,2.   

Abstract

Resistant hypertension (RH) was defined many years ago as a clinical situation in which blood pressure remains uncontrolled despite concomitant intake of at least three antihypertensive drugs (one of them preferably being a diuretic) at full doses. This operative definition was aimed at identifying a subset of hypertensive patients requiring a more extensive clinical workup in order to achieve an adequate blood pressure control. An oversimplification of this picture led to consider RH as a separate clinical entity requiring special, expensive treatments, such as renal denervation and baroreceptor activating therapy. In this review we will discuss the utility and the shortcomings of the definition of RH and the possible consequences for treatment.

Entities:  

Keywords:  Resistant hypertension; ambulatory blood pressure; definition

Year:  2016        PMID: 30310440      PMCID: PMC6159429          DOI: 10.15420/ecr.2016.11.1

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN: 1758-3756


  39 in total

1.  Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea.

Authors:  Gianfranco Parati; Carolina Lombardi; Jan Hedner; Maria R Bonsignore; Ludger Grote; Ruzena Tkacova; Patrick Levy; Renata Riha; Claudio Bassetti; Krzysztof Narkiewicz; Giuseppe Mancia; Walter T McNicholas
Journal:  J Hypertens       Date:  2012-04       Impact factor: 4.844

2.  Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Authors:  Stella Douma; Konstantinos Petidis; Michael Doumas; Panagiota Papaefthimiou; Areti Triantafyllou; Niki Kartali; Nikolaos Papadopoulos; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal:  Lancet       Date:  2008-06-07       Impact factor: 79.321

3.  A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients.

Authors:  Fadl Elmula M Fadl Elmula; Paola Rebora; Anneli Talvik; Sabrina Salerno; Eliza Miszkowska-Nagórna; Xiaoqiu Liu; Marika Heinpalu-Kuum; Tommaso Comotti; Anne C Larstorp; Morten Rostrup; Ewa Świerblewska; Maria Grazia Valsecchi; Sverre E Kjeldsen; Margus Viigimaa; Krzysztof Narkiewicz; Gianfranco Parati; Stéphane Laurent
Journal:  J Hypertens       Date:  2015-12       Impact factor: 4.844

4.  Resistant hypertension: do all definitions describe the same patients?

Authors:  L Boswell; J Pascual; A Oliveras
Journal:  J Hum Hypertens       Date:  2015-01-15       Impact factor: 3.012

5.  Prevalence of resistant hypertension in 1810 patients followed up in a specialized outpatient clinic and its association with the metabolic syndrome.

Authors:  Konstantinos Tziomalos; Lambrini Kirkineska; Maria Baltatzi; Elias Efthymiou; Konstantia Psianou; Natalia Papastergiou; Dimitra Magkou; Georgios Zervopoulos; Giannis Kagelidis; Eleni Karlafti; Christos Savopoulos; Apostolos I Hatzitolios
Journal:  Blood Press       Date:  2013-02-12       Impact factor: 2.835

6.  Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension.

Authors:  Rodrigo P Pedrosa; Luciano F Drager; Carolina C Gonzaga; Marcio G Sousa; Lílian K G de Paula; Aline C S Amaro; Celso Amodeo; Luiz A Bortolotto; Eduardo M Krieger; T Douglas Bradley; Geraldo Lorenzi-Filho
Journal:  Hypertension       Date:  2011-10-03       Impact factor: 10.190

Review 7.  The correct administration of antihypertensive drugs according to the principles of clinical pharmacology.

Authors:  Stefano Taddei; Rosa Maria Bruno; Lorenzo Ghiadoni
Journal:  Am J Cardiovasc Drugs       Date:  2011       Impact factor: 3.571

Review 8.  Sleep loss and hypertension: a systematic review.

Authors:  Laura Palagini; Rosa Maria Bruno; Angelo Gemignani; Chiara Baglioni; Lorenzo Ghiadoni; Dieter Riemann
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  Prognostic influence of office and ambulatory blood pressures in resistant hypertension.

Authors:  Gil F Salles; Claudia R L Cardoso; Elizabeth S Muxfeldt
Journal:  Arch Intern Med       Date:  2008-11-24

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.